Charles River Laboratories International

Charles River Laboratories International, Inc. provides solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. Segments The company has two segments: Research Models and Services (RMS) and Preclinical Services (PCS), which includes Phase I clinical services. RESEARCH MODELS AND SERVICES (RMS) The company supplies research models to the drug development industry. With approximately 150 different strains the company engages in the production and sale of research models, principally genetically and virally defined purpose-bred rats and mice. It also provides various related services that are designed to assist customers in supporting the use of research models in drug development. With multiple facilities located on three continents (North America, Europe and Asia (Japan)), the company maintains production centers, including a total of approximately 180 barrier rooms or isolator facilities located near its customers. RMS segment comprises Research Models, Research Model Services, and other related products and services

Charles River Laboratories International, established in 1947 and headquartered in United States, North America., specializes in Seed, Early Stage Venture investments across Biotechnology, Life Science, Financial Services, Venture Capital, Finance, Mobile, Angel Investment, Impact Investing, Consulting, Advice. The organization boasts a portfolio of 11 investments, with an average round size of $24.7M and 1 successful exits. Their recent investments include Ability biologics, Fonds de solidarité FTQ, Amplitude Venture Capital, Investissement Quebec, Alexandria Venture Investments. The highest investment round they participated in was $24.3B. Among their most notable exits are Ability biologics and Fonds de solidarité FTQ. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.